Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 8/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19521183 | 0.92 | CCR1 (0.41) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL19541329 | 0.83 | CCR1 (0.44) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL19521260 | 0.83 | CCR1 (0.44) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL19521259 | 0.83 | CCR1 (0.44) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL19521261 | 0.83 | CCR1 (0.44) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20969153 | 0.80 | ADAMTS5 (0.50) | CCR1 | |
| SCHEMBL20969263 | 0.76 | ALDH1A1 (0.46) | ALDH1A1MEN1KMT2A | |
| SCHEMBL20168992 | 0.75 | MMP2 (0.32) | — | |
| SCHEMBL12702339 | 0.74 | OPRK1 (0.56) | CCR1OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL20169007 | 0.74 | CHRM1 (0.38) | ALDH1A1HSD11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | Temple University—Of the Commonwealth System of Higher Education (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | Temple University--of the Commonwealth System of Higher Education | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759750-B2 | Beta lactams as modulators of glutamate uptake and methods for use thereof | SLC1A2, SLC1A1, SLC7A11 | CCR1 3301/4885OPRL1 240/4885OPRM1 156/4885 |
| US-20190127323-A1 | Novel Beta Lactams as Modulators of Glutamate Uptake and Methods for Use Thereof | SLC1A2, SLC1A1, SLC7A11 | CCR1 4161/4885OPRL1 206/4885OPRM1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.